New York, Jan 7, 2026, 11:10 EST — Regular session
- Abivax’s U.S.-listed shares rose about 7% in morning trade, outpacing biotech ETFs.
- The move keeps focus on a stock that has swung sharply on trial milestones and deal chatter.
- Next catalysts include the J.P. Morgan healthcare conference next week and a key IBD congress in February.
Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares.
The French biotech’s U.S.-listed stock has become a fast-moving name for healthcare traders, in part because its valuation rests on a single late-stage drug program. Its American depositary shares, or ADSs, are U.S.-traded certificates that represent ownership of a foreign company’s shares.
Abivax is developing obefazimod, an oral treatment candidate for ulcerative colitis, a chronic inflammatory bowel disease. The company said last July that its Phase 3 induction studies met their main goals and that top-line data from the longer “maintenance” phase — the follow-on period meant to show durability — are expected in the second quarter of 2026. Abivax
The broader biotech tape was firmer on Wednesday. The SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF were both up about 2% in morning trade, giving high-beta drug developers room to rebound.
Abivax has also been a frequent target of deal talk. Reuters reported in December that its Paris-listed shares climbed on market rumours of a possible Eli Lilly approach, and Stifel analyst Damien Choplain said at the time the move was driven by “speculation around a possible takeover.” Reuters
Near-term, investors will be scanning sector read-through from the annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 12-15, a venue that often brings fresh guidance and sharper questions on pipelines.
But the setup cuts both ways. Abivax has no product revenue, and a stock priced for success can drop fast on trial delays, a safety signal, or a tougher regulatory path. A quieter news cycle can also sap takeover premiums that some investors still price in.
